English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Vagus nerve stimulation ( VNS ) is effective in refractory epilepsy and depression and is being investigated in heart failure, headache, gastric motility disorders and asthma. The first  VNS  device required surgical implantation of electrodes and a stimulator. Adverse events ( AE s) are generally associated with implantation or continuous  on−off  stimulation. Infection is the most serious implantation‐associated  AE . Bradycardia and asystole have also been described during implantation, as has vocal cord paresis, which can last up to 6 months and depends on surgical skill and experience. The most frequent stimulation‐associated  AE s include voice alteration, paresthesia, cough, headache, dyspnea, pharyngitis and pain, which may require a decrease in stimulation strength or intermittent or permanent device deactivation. Newer non‐invasive  VNS  delivery systems do not require surgery and permit patient‐administered stimulation on demand. These non‐invasive  VNS  systems improve the safety and tolerability of  VNS , making it more accessible and facilitating further investigations across a wider range of uses.

Surgically implanted and non‐invasive vagus nerve stimulation: a review of efficacy, safety and tolerability